Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil Fumarate Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open-Label, Prospective Study

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 3, 2011, Pages 163-170

  Huang, Fenglei ^a   Scholl, Paul ^a   Huang, David B ^a   MacGregor, Thomas R ^a   Taub, Mitchell E ^a   Vinisko, Richard ^a   Castles, Mark A ^a   Robinson, Patrick ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILR 355 PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; APPETITE; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; FLATULENCE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AZEPINES; CROSS-OVER STUDIES; DEOXYCYTIDINE; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHOSPHONIC ACIDS; PYRIDINES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; YOUNG ADULT;

EID: 79951750503     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00636.x     Document Type: Article

References (37)

1. Yeni P. Update on HAART in HIV. J Hepatol 2006;44:S100-3.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
3. Munoz de Benito RM, rribas Lopez JR. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. Expert Rev Anti Infect Ther 2006;4:523-35.
4. Flexner C. Antiretroviral agents and treatment of HIV infection. In: Brunton LL, Lazo JS, Parker KL (eds). Goodman & Gilman's Pharmacological Basis of Therapeutics, 11 edn. McGraw-Hill Inc, New York, 2006;1273-1314.
5. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-60.
6. Boone LR. Next-generation HIV-non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs 2006;7:128-35.
7. De Clercq E. What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections? Rev Med Virol 1996;6:97-117.
8. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med Res Rev 1996;16:125-57.
9. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers 2004;1:44-64.
10. Bonneau P, Robinson PA, Duan J, Doyon L, Simoneau B, Yoakim C et al. Antiviral Characterization and Human Experience with BILR 355 BS, a Novel Next-Generation Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) with a Broad AntiHIV-1 Profile. 12th Conference on Retroviruses and Opportunistic Infections. Boston, Feb 22-25, 2005; Abstract # 558.
11. Huang F, Koenen-Bergmann M, MacGregor TR, Ring A, Hattox S, Robinson P. Pharmacokinetic and safety evaluation of BILR 355, a second generation non-nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2008;52:4300-7.
12. Huang F, Drda K, MacGregor TR, Scherer J, Rowland L, Nguyen T et al. Pharmacokinetics of BILR 355 after multiple oral dosing co-administered with low dose of ritonavir. Antimicrob Agents Chemother 2009;53:95-103.
13. ® in healthy volunteers. 2009 American Association of Pharmaceutical Scientists Annual Meeting. Los Angels, CA; November 8-12, 2008.
14. Huang F, Scholl P, Huang DB, MacGregor TR, Vinisko R, Castles MA et al. Co-administration with lopinavir and ritonavir (LPV/r) decreases the exposure to BILR 355, a non-nucleoside reverse transcriptase inhibitor (NNRTI), in healthy volunteers. J Clin Pharmacol 2010; doi: [Epub ahead of print].
15. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1991;29:1-8.
16. Blum MR, Chittick GE, Begley JA, Zong J. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol 2007;47:751-9.
17. Ramanathan S, Shen G, Cheng A, Kearney BP. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007;45:274-9.
18. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43:595-612.
19. Cihlar T, Ray AS, Laflamme G, Vela JE, Tong L, Fuller MD et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007;12:267-72.
20. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007;51:3498-504.
21. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50:3297-304.
22. Ray AS, Cihlar T. Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events. J Infect Dis 2007;195:1389-90.
23. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008;83:265-72.
24. Ford SL, Murray SC, Anderson MT, Ng-Cashin J, Johson MA, Shelton MJ. Tenofovir renal clearance decreased following co-administration with brecanavir/ritonavir. 7th International workshop on clinical pharmacology of HIV therapy. Lisbon, Portugal; 20-22 April, 2006.
25. Nakatani-Freshwater T, Taft DR. Renal excretion of emtricitabine I: effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion. J Pharm Sci 2008;97:5401-10.
26. Nakatani-Freshwater T, Taft DR. Renal excretion of emtricitabine II. Effect of trimethoprim on emtricitabine excretion: in vitro and in vivo studies. J Pharm Sci 2008;97:5411-20.
27. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P et al. Transport of lamivudine [(-)-beta-L-2', 3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 2009;329:252-61.
28. Takubo T, Kato T, Kinami J, Hanada K, Ogata H. Effect of trimethoprim on the renal clearance of lamivudine in rats. J Pharm Pharmacol 2000;52:315-20.
29. Nakatani-Freshwater T, Babayeva M, Dontabhaktuni A, Taft DR. Effects of trimethoprim on the clearance of apricitabine, a deoxycytidine analog reverse transcriptase inhibitor, and Lamivudine in the isolated perfused rat kidney. J Pharmacol Exp Ther 2006;319:941-7.
30. Moore KH, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 1996;59:550-8.
31. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van LJ et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 2008;36:1616-23.
32. Huang F, MacGregor TR, Yong C-L, Fu Y, Quinson A-M, Castles MA et al. Mixed effects pharmacokinetic modeling of BILR 355 and its major metabolite BILR 516. 2009 American Association of Pharmaceutical Scientists Annual Meeting. Los Angels, CA; November 8-12, 2008.
33. Li Y, Lai G, Xu J, Applegreen A, Tweedie D. Metabolic switching of BILR 355 in the presence of ritonavir II: elucidation of metabolic pathway for the formation of BILR 516. The 16th North American Regional ISSX Meeting, Baltimore, Maryland, October 18-22, 2009, poster #201. Drug Metab Rev; 41(Suppl. 3).
34. Bousquet L, Pruvost A, Didier N, Farinotti R, Mabondzo A. Emtricitabine: inhibitor and substrate of multidrug resistance associated protein. Eur J Pharm Sci 2008;35:247-56.
35. Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother 2009;53:896-902.
36. Wang LH, Begley J, St Claire RL III, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004;20:1173-82.
37. Rousseau FS, Kahn JO, Thompson M, Mildvan D, Shepp D, Sommadossi JP et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother 2001;48:507-13.